Core Insights - Microbot Medical Inc. is preparing for the full market release of its LIBERTY Endovascular Robotic System in April 2026, following a successful limited market release that began in late 2025 [3][4] - The company will present at the Roth Annual Growth Conference on March 23, 2026, where CEO Harel Gadot will discuss recent achievements and the unique aspects of the LIBERTY system [1][2] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY system is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [3][4] Market Strategy - The company aims to leverage the Roth conference to showcase its commercial momentum and growth story to a diverse audience, which is expected to support its current position and future growth [3] - The LIBERTY system addresses critical unmet healthcare needs, including physician safety and staffing issues, which are increasingly important in the medical field [3]

Core Insights - Microbot Medical Inc. is participating in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, indicating growing market interest in the company and its products [1][3] - The CEO, Harel Gadot, will present on March 19, 2026, focusing on the achievements and market growth drivers related to the LIBERTY Endovascular Robotic System [1][3] - The LIBERTY system is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, aimed at improving precision and reducing radiation exposure [3][4] Company Overview - Microbot Medical Inc. is a commercial stage medical device company dedicated to transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY Endovascular Robotic System is designed for precision, efficiency, and safety, supported by a strong intellectual property portfolio [4] Market Strategy - The limited market release of the LIBERTY system began in late 2025, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3] - The company aims to deepen market adoption by showcasing LIBERTY at key industry events [3]

Core Insights - Microbot Medical Inc. is not experiencing any business disruption due to current geopolitical events, prioritizing employee safety and operational continuity [1][4] - The company has shifted its commercial focus to the U.S. market following FDA clearance of the LIBERTY Endovascular Robotic System, ensuring reliable distribution and service [2] - A full market release of the LIBERTY System is planned for the Society of Interventional Radiology (SIR) conference in April 2026, with efforts to enhance commercial infrastructure [3][5] Company Operations - The company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through a third-party logistics partner [2] - Additional sales representatives have been hired to expand coverage into new U.S. territories, along with a Director of Health Economics and Outcomes Research to support commercial expansion [3] Product Information - The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to reduce radiation exposure and physical strain [5][6] - The limited market release of the LIBERTY system commenced in late 2025, with the goal of deepening market adoption during the full release [5]

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone for the company in the commercialization of this innovative medical device [2][3] - The CEO, Harel Gadot, will discuss the implications of this FDA clearance and the company's commercialization plans during a live interview on Benzinga All Access [1] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY® Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [3] - The company is backed by a strong intellectual property portfolio and is committed to innovation in the field of endovascular care [3]

Core Viewpoint - Microbot Medical Inc. has successfully closed the first tranche of a preferred investment options offering, raising approximately $25.2 million, with a second tranche expected to yield an additional $4 million, and potential gross proceeds of up to $63 million from future exercises of short-term preferred investment options [1][4]. Group 1: Offering Details - The first closing involved the exercise of preferred investment options to purchase up to 12,064,627 shares of common stock at exercise prices ranging from $1.50 to $2.13 per share [2]. - The second closing is anticipated by October 15, 2025, and will involve the exercise of options for 1,924,488 shares at an exercise price of $2.10 per share, with new options issued at $4.50 per share [2][4]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards the development, commercialization, and regulatory activities for the LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4]. Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [7].